Insulet (PODD) Tops Q2 EPS by 10c, Lowers FY Guidance

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.03), $0.10 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $124.26 million versus the consensus estimate of $132.86 million.

GUIDANCE:

Insulet sees Q3 2018 revenue of $144-151.5 million

Insulet sees FY 2018 revenue of $547-562 million, prior was for $565-580 million.

"The Company is raising its revenue expectations for U.S. Omnipod and Drug Delivery."

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ:
• Yext, Inc. (YEXT) Tops Q2 EPS by 4c
• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance